CG Oncology, Inc. (CGON): who owns it and who trades it
As of Nov 16, 2026, CGON insiders reported 17 open-market sales worth $4.8M and 1 purchase worth $24.8M in the last 12 months, with 4% of the sale value made under pre-set 10b5-1 plans. The largest seller was James Mulay (Director), with $3.8M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling CG Oncology
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CGON
226 funds and institutions reported CGON shares worth $6.7B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Rtw Investments, LP with 10.1%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Rtw Investments, LP | 8.51M | 10.08% | $605M | +22% |
| T. Rowe Price Investment Management, Inc. | 6.62M | 7.84% | $470M | -2% |
| Decheng Capital LLC | 6.37M | 7.55% | $453M | No change |
| BlackRock, Inc. | 6.26M | 7.41% | $445M | +24% |
| Wellington Management Group LLP | 5.32M | 6.31% | $378M | -1% |
| FMR LLC (Fidelity) | 4.16M | 4.93% | $296M | +11% |
| T. Rowe Price Associates | 3.81M | 4.51% | $270M | +4% |
| TCG Crossover Management, LLC | 3.67M | 4.35% | $261M | No change |
| Vanguard Portfolio Management LLC | 3.47M | 4.10% | $246M | +12% |
| State Street Corp | 3.44M | 4.07% | $244M | +30% |
| Vanguard Capital Management LLC | 3.32M | 3.93% | $236M | +9% |
| Foresite Capital Management VI LLC | 2.37M | 2.81% | $168M | +7% |
| Geode Capital Management, LLC | 2.15M | 2.55% | $153M | +35% |
| Seven Fleet Capital Management LP | 1.89M | 2.23% | $134M | +2390% |
| EcoR1 Capital, LLC | 1.49M | 1.77% | $106M | +36% |
| DV Trading LLC | 1.44M | 1.70% | $102M | No change |
| Avidity Partners Management LP | 1.40M | 1.66% | $99.4M | +9% |
| Alliancebernstein L.P. | 1.37M | 1.63% | $93M | +7% |
| Franklin Resources Inc | 1.31M | 1.55% | $93.3M | -13% |
| Morgan Stanley | 1.18M | 1.39% | $83.6M | +126% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CGON insiders reported $24.8M of open-market purchases and $4.8M of sales. 4% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 15, 2026 | Leonard E Post | Director | Sale plan | 500 | $61.65 | $30.8K | Form 4 |
| Oct 15, 2026 | Leonard E Post | Director | Sale plan | 500 | $62.48 | $31.2K | Form 4 |
| Sep 15, 2026 | Leonard E Post | Director | Sale | 1,000 | $72.98 | $73K | Form 4 |
| Aug 14, 2026 | Leonard E Post | Director | Sale | 1,000 | $74.54 | $74.5K | Form 4 |
| Jul 15, 2026 | Leonard E Post | Director | Sale | 1,000 | $71.17 | $71.2K | Form 4 |
| Jul 10, 2026 | James Mulay | Director | Sale | 24,165 | $75.16 | $1.8M | Form 4 |
| Jun 25, 2026 | Brian Guan-Chyun Liu | Director | Purchase | 371,085 | $66.87 | $24.8M | Form 4 |
| Jun 24, 2026 | Leonard E Post | Director | Sale | 5,000 | $70.00 | $350K | Form 4 |
| Jun 22, 2026 | Leonard E Post | Director | Sale | 5,000 | $65.00 | $325K | Form 4 |
| Jun 15, 2026 | James Mulay | Director | Sale plan | 1,310 | $60.12 | $78.8K | Form 4 |
| Jun 15, 2026 | James Mulay | Director | Sale plan | 654 | $60.12 | $39.3K | Form 4 |
| Jun 4, 2026 | Leonard E Post | Director | Sale | 1,000 | $54.50 | $54.5K | Form 4 |
| Apr 17, 2026 | James Mulay | Director | Sale | 15,600 | $73.01 | $1.1M | Form 4 |
| Mar 16, 2026 | James Mulay | Director | Sale | 654 | $63.50 | $41.5K | Form 4 |
| Mar 16, 2026 | James Mulay | Director | Sale | 1,310 | $63.50 | $83.2K | Form 4 |
| Jan 9, 2026 | James Mulay | Director | Sale | 10,491 | $52.99 | $556K | Form 4 |
| Jan 9, 2026 | James Mulay | Director | Sale | 654 | $44.16 | $28.9K | Form 4 |
| Nov 17, 2025 | Leonard E Post | Director | Sale | 1,000 | $41.43 | $41.4K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Brian Guan-Chyun Liu | Director | $24.8M | – | Jun 25, 2026 |
| James Mulay | Director | – | $3.8M | Jul 10, 2026 |
| Leonard E Post | Director | – | $1.1M | Oct 15, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CGON short interest
High short interest. 10.4% of CGON shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short barely changed.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 9.22M CGON shares were sold short, 10.4% of the shares outstanding, up 3.9% from the report before. At the average daily volume of 840,614 shares, buying them all back would take about 11.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 9.22M | 10.40% | +4% | 840,614 | 11.0 |
| Oct 15, 2026 | 8.87M | 10.01% | -15% | 919,379 | 9.7 |
| Sep 30, 2026 | 10.44M | 11.78% | -7% | 1.23M | 8.5 |
| Sep 15, 2026 | 11.25M | 12.70% | -1% | 661,528 | 17.0 |
| Aug 31, 2026 | 11.40M | 12.86% | +1% | 709,063 | 16.1 |
| Aug 14, 2026 | 11.25M | 12.69% | -5% | 757,562 | 14.8 |
| Jul 31, 2026 | 11.84M | 14.03% | -2% | 875,547 | 13.5 |
| Jul 15, 2026 | 12.11M | 14.34% | +0% | 989,354 | 12.2 |
| Jun 30, 2026 | 12.07M | 14.29% | +14% | 1.59M | 7.6 |
| Jun 15, 2026 | 10.56M | 12.51% | +8% | 909,472 | 11.6 |
| May 29, 2026 | 9.81M | 11.62% | +7% | 966,552 | 10.2 |
| May 15, 2026 | 9.18M | 10.87% | -0% | 917,955 | 10.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
CG Oncology company events
CG Oncology filed 10 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 6, 2026.
- Nov 6, 2026ResultsReleased financial results. Filing
- Aug 6, 2026AnnouncementThe Company filed Amendment No. 2 to Prospectus with the Securities and Exchange Commission for the offer and sale of shares of its common stock, par value $0.0001 per share, pursuant to that certain Open Market Sale Agreement, dated March 28, 2025, by and between the Company and Jefferies LLC, to… Filing
- Jun 8, 2026VoteReported shareholder vote results. Filing
- May 26, 2026LeadershipCG Oncology, Inc. and Ambaw Bellete, the Company’s President & Chief Operating Officer of the Company, agreed to his separation from the Company to be effective June 30, 2026. Filing
- May 8, 2026ResultsReleased financial results. Filing
- Apr 13, 2026LeadershipCG Oncology, Inc. appointed Jim DeTore as the Company’s Chief Financial Officer. Filing
- Feb 27, 2026ResultsReleased financial results. Filing
- Jan 13, 2026AnnouncementCG Oncology, Inc. filed Amendment No. 1 to Prospectus with the Securities and Exchange Commission for the offer and sale of shares of its common stock, par value $0.0001 per share, having an aggregate offering price of up to $550 million, pursuant to that certain Open Market Sale Agreement, dated… Filing
- Jan 9, 2026AnnouncementThe Company announced an expedited timeline for the topline data readout now expected in the first half of 2026 for the Phase 3 PIVOT-006 clinical trial comparing adjuvant intravesical cretostimogene grenadenorepvec versus surveillance in patients with intermediate-risk non-muscle invasive bladder… Filing
- Nov 26, 2025LeadershipThe Board of Directors of CG Oncology, Inc., upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Christina Rossi to the Company’s Board, effective November 24, 2025. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
CG Oncology financials
Famous investors that hold CGON
3 of the 50 well-known investors we track reported holding CGON in their latest 13F filing. The largest position is Ken Fisher's, worth $33.8M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Fisher · Fisher Asset Management | Q3 2026 | 476,917 | $33.8M | 0.0% | +4% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 63,440 | $4.5M | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 4,524 | $321K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about CG Oncology, Inc. (CGON) stock
Who owns the most CGON stock?
The largest reported owner of CG Oncology, Inc. (CGON) is Rtw Investments, LP, with 10.1% of the company. In total, 226 funds and institutions reported holding CGON at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are CGON insiders buying or selling?
In the last 12 months, CGON insiders reported 1 open-market purchase worth $24.8M and 17 sales worth $4.8M. The latest trade was on Oct 15, 2026. See every trade.
What is the short interest in CGON?
As of Oct 30, 2026, 9.22M CGON shares were sold short, 10.4% of the shares outstanding, up 3.9% from the report before. At the average daily volume of 840,614 shares, buying them all back would take about 11.0 trading days (days to cover). See the history.
Which famous investors hold CGON?
3 of the 50 well-known investors we track reported CGON in their latest 13F filing, including Ken Fisher, Ken Griffin, Israel Englander. The largest position is worth $33.8M. See all holders.
Executive pay
CG Oncology's chief executive was paid a total of $11.9M for the year ended Dec 31, 2025, up 7% from $11.2M the year before. In the last 12 months, CG Oncology's executives and directors bought $24.8M of stock on the open market and sold $4.8M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.